Home Newsfeeds Needham Reiterates Buy on Paycom Software, Maintains $450 Price Target

Needham Reiterates Buy on Paycom Software, Maintains $450 Price Target

Needham analyst Joshua Reilly reiterates Paycom Software (NYSE:PAYC) with a Buy and maintains $450 price target.

byBenzinga Newsdesk

February 8, 2023

1 minute read

Needham analyst Joshua Reilly reiterates Paycom Software (NYSE:PAYC) with a Buy and maintains $450 price target.

Analyst Ratings

4 Analysts Have This to Say About BankUnited

By Benzinga Insights

April 26, 12:00 PM

Analysts have provided the following ratings for BankUnited (NYSE:BKU) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…

BKU

If You Invested $100 In This Stock 15 Years Ago, You Would Have $700 Today

By Benzinga Insights

October 7, 12:37 PM

Lam Research (NASDAQ:LRCX) has outperformed the market over the past 15 years by 7.85% on an annualized basis producing an average annual return of 13.73%. Currently, Lam Research has a market capitalization of $51.51 billion.

LRCX

Union Pacific Shares Fall After Lowered Annual Volume Growth Forecast

By Vandana Singh

October 20, 9:18 AM

Union Pacific Corporation (NYSE:UNP) posted Q3 FY22 adjusted EPS of $3.19, beating the consensus of $3.08 and better than the…

UNP

Safety Shot Continues Scientific Development With Double-Blind Placebo-Controlled Trial Designed To Assess The Effects Of Safety Shot On Blood And Breath Alcohol Levels; Topline Data Expected Q1 2024

By Benzinga Newsdesk

November 24, 9:33 AM

Topline data expected Q1 2024Safety Shot is designed to make you feel good faster by reducing blood alcohol levels and improving clarityA double-blinded, placebo controlled, clinical trial designed to compare the effects

SHOT

Needham Reiterates Buy on Paycom Software, Maintains $450 Price Target

Related Posts

4 Analysts Have This to Say About BankUnited

If You Invested $100 In This Stock 15 Years Ago, You Would Have $700 Today

Union Pacific Shares Fall After Lowered Annual Volume Growth Forecast

Safety Shot Continues Scientific Development With Double-Blind Placebo-Controlled Trial Designed To Assess The Effects Of Safety Shot On Blood And Breath Alcohol Levels; Topline Data Expected Q1 2024